OTCMKTS:ASPHF Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis $4.53 0.00 (0.00%) As of 07/10/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Ascentage Pharma Group International Stock (OTCMKTS:ASPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ASPHF alerts:Sign Up Key Stats Today's Range$4.53▼$4.5350-Day Range$4.53▼$8.4852-Week Range$4.53▼$5.05VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ascentage Pharma Group International (OTCMKTS:ASPHF) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, with a strategic presence in the United States. The company focuses on the discovery and development of targeted small-molecule therapies that modulate programmed cell death, leveraging a deep understanding of the Bcl-2 family of proteins. Ascentage’s core activities center on the research and development of apoptosis regulators, including both Bcl-2 selective and dual Bcl-2/Bcl-xL inhibitors. Its diverse pipeline comprises several compounds in various stages of clinical and preclinical evaluation, addressing both hematological malignancies and solid tumors. The company’s R&D operations integrate proprietary chemistry platforms with translational biology to accelerate the progression of novel candidates through global regulatory pathways. The company serves markets across Greater China, North America, and Singapore, collaborating with contract research organizations and academic institutions worldwide. Through partnerships and strategic alliances, Ascentage aims to expand its clinical footprint and optimize trial execution, particularly for oncology indications with significant unmet medical needs. Founded in 2010 by a team of life science researchers, Ascentage has grown under a management team of industry veterans with extensive experience in drug discovery and development. This leadership combines academic insights with pharmaceutical expertise to drive innovation and establish the company as a global player in oncology therapeutics.AI Generated. May Contain Errors. Read More Receive ASPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASPHF Stock News HeadlinesAscentage Pharma Corrects AGM Date Underpinning Equity Incentive MandateJuly 13 at 8:51 PM | tipranks.comShort Interest in Ascentage Pharma Group International (OTCMKTS:ASPHF) Rises By 213.3%July 13 at 3:20 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 14 at 1:00 AM | Porter & Company (Ad)Ascentage Pharma Corrects AGM Date for Share Incentive Scheme MandateJuly 12 at 8:30 PM | tipranks.comAscentage Pharma Grants New RSUs to 453 Employees Under 2021 SchemeJune 29, 2026 | tipranks.comAscentage Pharma Showcases Broad Leukemia Data for Olverembatinib and Lisaftoclax at EHA2026June 14, 2026 | tipranks.comAscentage Pharma Trustee Buys Shares to Fund 2022 RSU SchemeJune 11, 2026 | tipranks.comAscentage Pharma Trustee Buys Shares to Fund 2022 RSU Incentive SchemeJune 10, 2026 | tipranks.comSee More Headlines ASPHF Stock Analysis - Frequently Asked Questions How have ASPHF shares performed this year? Ascentage Pharma Group International's stock was trading at $8.48 on January 1st, 2026. Since then, ASPHF shares have decreased by 46.6% and is now trading at $4.53. How do I buy shares of Ascentage Pharma Group International? Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/14/2026Next Earnings (Estimated)8/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:ASPHF CIKN/A Webwww.ascentagepharma.com Phone86-512-8555-7777FaxN/AEmployees565Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:ASPHF) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredBehind Trump's $250 BillFinancial forecaster Porter Stansberry says Trump is planning to replace the U.S. dollar - not with crypto or ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.